Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (January 2020)
22 slides from Genprex's investor presentation, Jan 9, 2020
Slide 1: Reprogramming the Course of Cancer
© Genprex REPROGRAMMING THE COURSE OF CANCER NASDAQ: GNPX
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Actof 1995. Because such statements are subject to risks and uncertainties, actual resu
Slide 3: 21st Century Gene Therapy for Cancer
21ST CENTURY GENE THERAPY FOR CANCER LEARNING FROM THE PAST TO TREAT PATIENTS IN THE PRESENT, WITH TECHNOLOGY EQUIPPED TO CHANGE THE FUTURE WHO WE ARE Genprex, Inc. isa clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform
Slide 4: Company Highlights
COMPANY HIGHLIGHTS KEY CORPORATEACHIEVEMENTS. Genprexis developing potentially life-changing gene technologies based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy. ‘A Phase | clinical trial showed that Intern dats fom 6 Phocs U
Slide 5: Problem: Few Patients Benefit from Modern Therapies
PROBLEM: FEW PATIENTS BENEFIT FROM MODERN THERAPIES LIMITATIONS TO NSCLC TREATMENT TARGETED THERAPIES IMMUNOTHERAPIES PATIENT ELIGIBILITY Of patients havean activating Of patients are eligible for EGFR mutation and can benefit and benefit from from targeted therapies! immunotherapies? “Few patients
Slide 6: Solution: Novel Platform to Treat Cancer
SOLUTION: NOVEL PLATFORM TO TREAT CANCER GENES Multiple tumor suppressor genes SYNERGIES Modern approach using combination therapy CANCERS Genetic mutations found in other cancers Genprex Nasdaq: GNX
Slide 7: Oncoprex Targets Cancer at Its Core
ONCOPREX™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 } 23 e- eo os °* CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS = MODULATES IMMUNE RESPONSE Pan-kinase inhibition decreases cell Leads to programmed cell death Promotes immune activity against proliferation cancer Nasdaq: GNPX
Slide 8: Oncoprex Inhibits Key Cell Signaling
ONCOPREX INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Nasdaq: GNPX
Slide 9: Oncoprex Affects Tumor Immunogenicity
ONCOPREX AFFECTS TUMOR IMMUNOGENICITY TUSC2 ALSO SHOWN TO UPREGULATE NK AND CD8+ T CELLS, AND DOWNREGULATE PD-L1 RECEPTORS IL15 mRNA A A a a“ : > S) & Ribosome Is 2 IL15 Immature Mature NK cells NK cells Nasdaq: GNPX
Slide 10: Nanovesicle Delivery System
NANOVESICLE DELIVERY SYSTEM CATIONIC LIPID NANOVESICLE CARRIES DRUG TO TUMORS Positively charged nanovesicle ° ° Negatively charged cancer cell Nanovesicle attaches to Cancer‘killing genes Cell death cancer cell like a magnet integrate into cell Our non-viral, biodegradable, positively-charged lipid
Slide 11: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE PATHWAY TO APPROVAL PRECLINICAL CLINICAL CLINICAL CLINICAL PHASE 1 PHASE 2 PHASE 3 ONCOPREX + ONCOPREX + FIRST GENERATION EGER INHIBITOR TARGETED pete THERAPIES ele ane nia ONCOPREX + phan PVVINRAERSRI | CHECKPOINT INHIBITOR Nasdaq: GNPX
Slide 12: Oncoprex Dose Escalation Study
ONCOPREX DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase | monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=3 Maximum Tolerated Dose (MTD) established W
Slide 13: Oncoprex + Erlotinib Combination
ONCOPREX + ERLOTINIB COMBINATION PHASE II PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PATIENT EGFR STATUS RESPONSE PRIOR THERAPY eee Positive (exon 18+20) Chemo Negative 24% regression Target Lesion Chemo /anti-PD1 2 30% regression one Target Lesion Negative 18% regression all Target
Slide 14: Oncoprex + Erlotinib Combination Swimmer Plot
EGFR status/mutation ONCOPREX + ERLOTINIB COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negative 4 sD Negative 4 Positive (exon 18+20) 4 Negative 4 Negative 4 Negative 4 Negative 4 Negative 4 Positive (exon 21) 4 Negative 4 Negative 4 Positive (exon 21) 4 * Chemotherapy ‘4 Chemother
Slide 15: Oncoprex Shows Synergy with Immunotherapies
ONCOPREX SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER Survival on Lung Metastasis Model Non-Treated ‘TUSC2-Treated z = tusee = <= tusc2+P01 i wo — Tuscarora od 6 78 % Pa Days . . TUSC2+anti-PD1 combination significantly prolonged TUS
Slide 16: Oncoprex Shows Synergy with Immunotherapies
ONCOPREX SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 IN A HUMANIZED MOUSE MODEL OF LUNG CANCER TUSC2 + PEMBRO TUSC2 + PEMBRO + CHEMO Strong antitumor immune responses of anti-PD1 TUSC2+anti-PD1+chemo combination resulted were found against PDX tumors developed in inmetastas
Slide 17: Timeline
TIMELINE HIGHLIGHTS FROM OUR JOURNEY 2018 Initiated adaitional pre- clinical research with MDACC or Oncoprex= immunotherapies 2015 ‘Commenced intial preclinical studies evaluating Oncoprex incombination with immunotherapies 2009 Genprexwas founded 2012 Phasel monotherapy clinical trial of Oncoprex i
Slide 18: Key Milestones 2020
KEY MILESTONES 2020 MANUFACTURING + Complete preparation of lipid nanoparticl delivery system and TUSC2 DNA plasmid for clinical expansion + Complete manufacturing scale-up to support trial site expansion and commercial-scale development RESEARCH & DEVELOPMENT + Pursue additional prediinical researc
Slide 19: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman & CEO + 30+ years of expertise in corporate law, including corporate governance, in biotech industry + Former owner of securities broker dealer firm RYAN CONFER, MS CFO + 10+ years of C-Level experience in emerging technology companies: + E
Slide 20: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD, FACS, Chairman PASI ANTERO JANNE MD, PhD + Professor and Bud Johnson Distinguished Clinical Chair, Department of Thoracic and Cardiovascular Surgery; Chief, Section of ThoracicMolecular Oncology; Professor of Molecular and Cellular Oncology; U
Slide 21: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD ROBERT PEARSON, MBA Chairman of the Board Board Director + 30+ years of expertise in corporate law, including + Strategic Advisor, W20 Group corporate governance, in biotech industry + Deep global media and communications experience + Former owner o
Slide 22: Contact Information
© Genprex NASDAQ: GNPX 1601 Trinity St, Bldg B, Suite 3.322, Austin TX 78712 | 1 Broadway, Cambridge, MA02142 (877)774-GNPX | investors@genprex.com Nasdaq: GNPX